Derazantinib hydrochloride is under clinical development by Basilea Pharmaceutica International and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase III drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Derazantinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Derazantinib hydrochloride overview

Deranzantinib hydrchloride (ARQ-087) is under development for the treatment of adrenocortical tumors, advanced solid tumors and urothelial cell carcinoma. The drug candidate is administered orally. ARQ-087 is an inhibitor of pan-fibroblast growth factor receptor (FGFR) and CSF1R. The drug candidate is based on proprietary structure-based drug design technology known as the ArQule Kinase Inhibitor Platform (AKIP).

It was also under development for the treatment of gastric cancer, intrahepatic cholangiocarcinoma (iCCA) and adenocarcinoma of the gastroesophageal junction.

Basilea Pharmaceutica International overview

Basilea Pharmaceutica International, a subsidiary of Basilea Pharmaceutica Ltd, is a manufacturer and supplier of inorganic and organic medicinal chemicals.

For a complete picture of Derazantinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.